{
  "id": "tumor_lysis_syndrome_cues_selectAll_v1",
  "type": "selectAll",
  "stem": "The nurse is monitoring a client undergoing aggressive chemotherapy for leukemia. Which findings or laboratory results indicate the development of Tumor Lysis Syndrome (TLS)? Select all that apply.",
  "options": [
    {
      "id": "e",
      "text": "White blood cell count has dropped from 50,000 to 2,000/mmÂ³."
    },
    {
      "id": "a",
      "text": "Serum potassium level of 5.8 mEq/L (Hyperkalemia)."
    },
    {
      "id": "c",
      "text": "Serum phosphate level of 5.4 mg/dL (Hyperphosphatemia)."
    },
    {
      "id": "f",
      "text": "Urine output has decreased to 20 mL/hour with cloudy appearance."
    },
    {
      "id": "b",
      "text": "Serum uric acid level of 10.2 mg/dL (Hyperuricemia)."
    },
    {
      "id": "d",
      "text": "Serum calcium level of 7.2 mg/dL (Hypocalcemia)."
    }
  ],
  "correctOptionIds": [
    "a",
    "b",
    "c",
    "d",
    "f"
  ],
  "scoring": {
    "method": "polytomous",
    "scoringInstructions": "1 point for each correct selection, -1 point for each incorrect selection. Minimum score is 0.",
    "maxPoints": 5
  },
  "pedagogy": {
    "bloomLevel": "analyze",
    "cjmmStep": "recognizeCues",
    "nclexCategory": "Physiological Adaptation",
    "difficulty": 4,
    "topicTags": [
      "Oncology",
      "Metabolic Emergency",
      "Electrolyte Imbalance",
      "Acute Kidney Injury"
    ]
  },
  "answerBreakdown": [
    {
      "optionId": "e",
      "correct": false,
      "content": "**Incorrect.** A drop in WBC count indicates chemotherapy is working to lyse cells, which *causes* TLS, but is not a diagnostic criterion *of* TLS. TLS is defined by metabolic derangements (hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia) and end-organ damage (AKI). The nurse must recognize this as the trigger, not a defining feature. \n\n**Clinical Pearl:** Monitor patients closely after initiation of chemotherapy for signs of TLS, especially those with high tumor burden malignancies. Prophylactic measures such as hydration and allopurinol are crucial."
    },
    {
      "optionId": "a",
      "correct": true,
      "content": "**Correct.** Hyperkalemia is a hallmark of TLS. Chemotherapy-induced cell lysis releases large amounts of intracellular potassium into the bloodstream, overwhelming the kidneys' excretory capacity. \n\n**Pathophysiology:** Potassium is the major intracellular cation. Rapid cell lysis releases potassium into the extracellular fluid, leading to hyperkalemia. This excess potassium disrupts the normal resting membrane potential of cells, particularly cardiac myocytes. This can lead to life-threatening cardiac arrhythmias such as peaked T waves, QRS widening, ventricular fibrillation, and asystole.\n\n**Clinical Pearl:** Hyperkalemia is the most immediately life-threatening electrolyte abnormality in TLS. Continuous cardiac monitoring is essential. Treatment includes calcium gluconate (to stabilize cardiac membranes), insulin and glucose (to shift potassium intracellularly), and potassium-binding resins (to remove potassium from the body)."
    },
    {
      "optionId": "c",
      "correct": true,
      "content": "**Correct.** Hyperphosphatemia is a key indicator of TLS. Tumor cells, especially in rapidly proliferating malignancies, contain high intracellular phosphate concentrations. Cell lysis releases this phosphate into the serum.\n\n**Pathophysiology:** Tumor cells contain significantly higher concentrations of phosphate compared to normal cells. When these cells lyse, phosphate is released into the bloodstream. The kidneys' ability to excrete this excess phosphate is overwhelmed, leading to hyperphosphatemia. Elevated phosphate levels can lead to the formation of calcium phosphate precipitates, contributing to hypocalcemia and nephrocalcinosis, further exacerbating acute kidney injury.\n\n**Clinical Pearl:** Monitor phosphate levels closely. Phosphate binders may be necessary to reduce serum phosphate levels and prevent complications."
    },
    {
      "optionId": "f",
      "correct": true,
      "content": "**Correct.** Decreased urine output with cloudy appearance indicates acute kidney injury (AKI) secondary to TLS. The AKI is primarily due to obstructive nephropathy from uric acid and calcium phosphate crystal formation in the renal tubules.\n\n**Pathophysiology:** Hyperuricemia and hyperphosphatemia contribute to AKI. Uric acid precipitates in the acidic environment of the renal tubules, forming crystals that obstruct urine flow. Simultaneously, hyperphosphatemia leads to the formation of calcium phosphate crystals, which also deposit in the tubules. This crystal deposition causes physical obstruction, inflammation, and a decline in glomerular filtration rate (GFR), leading to oliguria and cloudy urine due to crystaluria.\n\n**Clinical Pearl:** Maintain adequate hydration to promote urine output and prevent crystal formation. Consider alkalinizing the urine to increase uric acid solubility."
    },
    {
      "optionId": "b",
      "correct": true,
      "content": "**Correct.** Hyperuricemia is a hallmark of TLS. Rapid cell destruction releases large quantities of nucleic acids, which are metabolized into uric acid. The kidneys' ability to clear this excess uric acid is overwhelmed.\n\n**Pathophysiology:** The breakdown of nucleic acids (DNA and RNA) from lysed tumor cells results in the production of purines. These purines are then metabolized by the liver into uric acid via the xanthine oxidase pathway. The sheer volume of purines released during TLS overwhelms this pathway and the kidneys' capacity to excrete uric acid, leading to hyperuricemia. Uric acid crystals can precipitate in the renal tubules, causing obstructive nephropathy and AKI.\n\n**Clinical Pearl:** Allopurinol or rasburicase are used to reduce uric acid levels. Rasburicase is more potent but also more expensive and carries a risk of anaphylaxis."
    },
    {
      "optionId": "d",
      "correct": true,
      "content": "**Correct.** Hypocalcemia occurs secondary to hyperphosphatemia in TLS. Elevated phosphate binds with serum calcium, forming insoluble calcium phosphate precipitates, reducing the level of ionized calcium.\n\n**Pathophysiology:** Hyperphosphatemia leads to the formation of calcium phosphate complexes, which deposit in tissues and reduce the amount of ionized (free) calcium in the circulation. This hypocalcemia increases neuromuscular excitability, leading to clinical signs such as tetany (Chvostek's and Trousseau's signs), seizures, and cardiac arrhythmias (prolonged QT interval).\n\n**Clinical Pearl:** Monitor calcium levels closely. If the patient is symptomatic, administer calcium gluconate. However, avoid aggressive calcium replacement, as it can exacerbate calcium phosphate precipitation and worsen AKI."
    }
  ],
  "questionTrap": "The primary trap is confusing the *cause* of TLS (cell lysis) with the *effects* that define the syndrome. The dropping WBC count indicates chemotherapy is lysing cells, which *causes* TLS. However, TLS is diagnosed by the specific metabolic abnormalities (hyperkalemia, hyperphosphatemia, hyperuricemia, and secondary hypocalcemia) and resulting organ dysfunction (e.g., AKI). Test-takers might incorrectly select the WBC drop because it is logically related, but it is not a defining feature of the syndrome according to diagnostic criteria like the Cairo-Bishop classification.",
  "mnemonics": "Remember the key lab findings of TLS with the mnemonic P-U-R-I-C:\n- P: Phosphate high (Hyperphosphatemia)\n- U: Uric acid high (Hyperuricemia)\n- R: Renal failure (Oliguria, elevated creatinine)\n- I: Increased Potassium (Hyperkalemia)\n- C: Calcium low (Hypocalcemia)",
  "sbar": {
    "situation": "The client is undergoing aggressive chemotherapy for leukemia and is at risk for Tumor Lysis Syndrome (TLS).",
    "background": "The client's chemotherapy regimen is known to cause rapid cell lysis. Baseline labs were within normal limits prior to chemotherapy initiation. Current WBC is dropping rapidly.",
    "assessment": "The nurse assesses the client at 1400 and notes the following: urine output decreased to 20 mL/hour with cloudy appearance, serum potassium 5.8 mEq/L, serum phosphate 5.4 mg/dL, serum uric acid 10.2 mg/dL, and serum calcium 7.2 mg/dL. Cardiac monitoring shows peaked T waves.",
    "recommendation": "The nurse recommends the following to the provider at 1415: STAT labs (CMP, uric acid, phosphate), continuous cardiac monitoring, IV hydration with normal saline at 150 mL/hr, administration of allopurinol or rasburicase, and consideration of kayexalate or dialysis if hyperkalemia is not responsive to medical management. Monitor urine output hourly and report any further decrease."
  },
  "sentinelStatus": "healed_v2026_v8"
}